Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Jun 6, 2024; 12(16): 2713-2721
Published online Jun 6, 2024. doi: 10.12998/wjcc.v12.i16.2713
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Exclusion criteria
Age ≥ 18 yr, male or femalePregnancy or lactation
Glogau photoaging score of II or IIISystemic diseases, such as diabetes, autoimmune diseases, and severe heart, liver, and kidney dysfunction
Residing in areas with an altitude of ≥ 1800 m for > 10 yrCurrent treatment with glucocorticoids, estrogen, and other drugs that may cause facial pigmentation and affect the experimental results
Voluntarily receiving intradermal injection of Sunmax Col for facial rejuvenation and signing informed consent formsFacial laser, freezing, and other treatments within the past 3 months
Facial filling or botulinum toxin injection within the past 6 months
Known allergies to Col or other ingredients in Sunmax Col
Failure to follow up as planned or data loss affecting the evaluation of efficacy
Table 2 Face-Q scale content
Scale name
Content
Face-Q-Satisfaction with Facial Appearance OverallEvaluates overall facial appearance
Face-Q-Satisfaction with SkinEvaluates facial skin texture, color, and overall appearance
Face-Q-Satisfaction with OutcomeEvaluates the results of facial cosmetic treatments
Face-Q-Satisfaction with DecisionEvaluates decision-making regarding facial cosmetic treatments
Face-Q-Social FunctionEvaluates the impact of facial appearance on social interactions
Face-Q-Psychological FunctionEvaluates the psychological impact of facial appearance
Face-Q-Adverse Effects: SkinEvaluates adverse reactions of the facial skin after treatment
Table 3 Comparison of skin thickness before and after intradermal injection of Col I (mm, mean ± SD)

Baseline
1st
2nd
3rd
4th
5th
6th
Right cheek1.65 ± 0.191.76 ± 0.22a1.88 ± 0.19a1.98 ± 0.16a2.04 ± 0.15a2.11 ± 0.17a2.15 ± 0.20a
Left cheek1.62 ± 0.211.69 ± 0.211.78 ± 0.191.90 ± 0.17a1.99 ± 0.12a2.06 ± 0.13a2.12 ± 0.16a
Right zygomatic1.57 ± 0.181.67 ± 0.201.79 ± 0.18a1.89 ± 0.16a1.96 ± 0.15a2.02 ± 0.14a2.08 ± 0.17a
Left zygomatic1.56 ± 0.221.63 ± 0.241.75 ± 0.231.86 ± 0.201.94 ± 0.18a2.01 ± 0.16a2.05 ± 0.15a
Right temple1.48 ± 0.251.54 ± 0.261.63 ± 0.241.75 ± 0.211.86 ± 0.181.96 ± 0.17a2.00 ± 0.20a
Left temple1.44 ± 0.241.52 ± 0.251.62 ± 0.261.73 ± 0.231.83 ± 0.201.94 ± 0.18a1.99 ± 0.16a
Table 4 Comparison of VISIA parameters before and after intradermal injection of type I collagen (feature count, mean ± SD)

Baseline
1st
2nd
3rd
4th
5th
6th
Red area374.55 ± 22.89325.25 ± 22.92a283.60 ± 23.08a244.35 ± 25.81a212.70 ± 28.48a189.85 ± 28.52a174.90 ± 27.18a
Wrinkles118.40 ± 16.43114.80 ± 16.26111.60 ± 16.64108.80 ± 16.39106.45 ± 16.21104.30 ± 15.48102.20 ± 15.29a
Table 5 Comparison of Face-Q-Satisfaction with Facial Appearance Overall and Face-Q-Satisfaction with Skin scores before and after intradermal injection of type I collagen (mean ± SD)

Baseline
1st
2nd
3rd
4th
5th
6th
Face-Q-Satisfaction with Facial Appearance Overall40.05 ± 15.0349.50 ± 14.86a57.50 ± 14.14a64.50 ± 12.47a72.50 ± 10.47a76.50 ± 9.56a80.40 ± 8.16a
Face-Q-Satisfaction with Skin34.05 ± 11.9845.5 ± 12.33a55.25 ± 11.91a63.5 ± 9.73a73.6 ± 8.69a78.35 ± 8.11a82.40 ± 6.72a
Table 6 Face-Q-Satisfaction with Outcome, Face-Q-Satisfaction with Decision, Face-Q-Social Function, Face-Q-Psychological Function, and Face-Q-Adverse Effects: Skin scores after 6 intradermal injections of type I collagen (mean ± SD)
Scale
Score
Face-Q-Satisfaction with Outcome67.05 ± 15.50
Face-Q-Satisfaction with Decision83.8 ± 14.50
Face-Q-Social Function76.5 ± 8.7
Face-Q-Psychological Function78.75 ± 7.5
Face-Q-Adverse Effects: Skin13.85 ± 3.82